Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OVID
stocks logo

OVID

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
78.25K
+2.96%
-0.110
-15.38%
50.00K
-61.54%
-0.112
-20%
50.00K
-99.2%
-0.118
+96.67%
Estimates Revision
The market is revising Downward the revenue expectations for Ovid Therapeutics Inc. (OVID) for FY2025, with the revenue forecasts being adjusted by -2.12% over the past three months. During the same period, the stock price has changed by 31.71%.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.12%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-2.58%
In Past 3 Month
Stock Price
Go Up
up Image
+31.71%
In Past 3 Month
Wall Street analysts forecast OVID stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OVID is 4.58 USD with a low forecast of 1.50 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast OVID stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OVID is 4.58 USD with a low forecast of 1.50 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.620
sliders
Low
1.50
Averages
4.58
High
7.00
Current: 1.620
sliders
Low
1.50
Averages
4.58
High
7.00
H.C. Wainwright
Buy
maintain
$2
2025-11-24
Reason
H.C. Wainwright
Price Target
$2
2025-11-24
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Ovid Therapeutics to $2 from $1.50 and keeps a Buy rating on the shares. OV329's initial clinical data show robust safety and position the compound favorably for proof-of-concept clinical development, the analyst tells investors in a research note.
Leerink
initiated
$5
2025-11-17
Reason
Leerink
Price Target
$5
2025-11-17
initiated
Reason
Leerink initiated coverage of Ovid Therapeutics with an Outperform rating and $5 price target.
Leerink
Marc Goodman
Outperform
initiated
$5
2025-11-17
Reason
Leerink
Marc Goodman
Price Target
$5
2025-11-17
initiated
Outperform
Reason
As previously reported, Leerink analyst Marc Goodman initiated coverage of Ovid Therapeutics with an Outperform rating and $5 price target. The firm notes OV329 is a second-gen GABA-AT inhibitor with greater potency and potentially improved safety, including the lack of retinal toxicity compared with the first-gen GABA-AT inhibitor. Leerink likes the epilepsy market; the FDA wants to approve new drugs, payer pushback is relatively low since patients are refractive to many AEDs, polypharmacy is the norm, so this is not a zero-sum game, and importantly physicians like to try new therapies. The firm believe the KCC2 portfolio represents an interesting opportunity targeting a novel mechanism with strong biological validation, as genetic and preclinical evidence links KCC2 dysregulation to developmental and neuropsychiatric disorders.
Lucid Capital
NULL -> Buy
initiated
$5.50
2025-08-13
Reason
Lucid Capital
Price Target
$5.50
2025-08-13
initiated
NULL -> Buy
Reason
Lucid Capital initiated coverage of Ovid Therapeutics with a Buy rating and $5.50 price target. The firm says Ovid is developing drugs to treat epilepsies and seizure-related neurological disorders. The company's OV329 could capture a significant market share in drug-resistant epilepsy, reaching over $1B in sales in the U.S., five years after launch, the analyst tells investors in a research note.
B. Riley
Buy
maintain
$3
2025-08-08
Reason
B. Riley
Price Target
$3
2025-08-08
maintain
Buy
Reason
B. Riley keeps a Buy rating on Ovid Therapeutics with a $3 price target following a transfer of coverage. The firm views OV329 as a "best-in-class contender" that could increase investor optimism.
H.C. Wainwright
Buy
downgrade
$2
2025-05-27
Reason
H.C. Wainwright
Price Target
$2
2025-05-27
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Ovid Therapeutics to $1.50 from $2 and keeps a Buy rating on the shares. Ovid currently trades at a negative enterprise value and remains slated to deliver multiple potential value inflection points over the next 12 months, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ovid Therapeutics Inc (OVID.O) is -3.55, compared to its 5-year average forward P/E of -3.17. For a more detailed relative valuation and DCF analysis to assess Ovid Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.17
Current PE
-3.55
Overvalued PE
-1.01
Undervalued PE
-5.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.36
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
6.38
Undervalued EV/EBITDA
-5.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
311.38
Current PS
0.00
Overvalued PS
860.00
Undervalued PS
-237.24
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 668.25% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

OVID News & Events

Events Timeline

(ET)
2025-12-02
07:10:00
Ovid Appoints Petra Kaufmann as Chief Medical Officer
select
2025-11-12 (ET)
2025-11-12
07:11:33
Ovid Therapeutics names Alexander as CEO and Levin as Executive Chairman
select
2025-11-12
07:10:26
Ovid Therapeutics announces Q3 earnings per share of 17 cents, surpassing consensus estimate of 15 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-02Globenewswire
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer to Advance CNS Drug Development
  • New Chief Medical Officer: Ovid Therapeutics has appointed Dr. Petra Kaufmann as Chief Medical Officer, responsible for guiding clinical, medical, and regulatory strategies to advance the company’s pipeline of potential best- and first-in-class therapeutic candidates for neuronal imbalance.
  • Extensive Drug Development Experience: Dr. Kaufmann brings a wealth of experience in CNS therapeutics, having served as CMO at Vigil Neuroscience and Novartis Gene Therapies, where she played a key role in the global approval of Zolgensma®, showcasing her expertise in developing drugs for complex neurological conditions.
  • Patient-Focused R&D Philosophy: Dr. Kaufmann emphasizes a patient-focused development approach, committed to advancing OV329 and the KCC2 portfolio through rigorous scientific mechanisms, ensuring that each program is guided by sound clinical principles and a deep understanding of patient needs.
  • Strategic Leadership Team Enhancement: Ovid's President Meg Alexander stated that Dr. Kaufmann's appointment will strengthen the company’s R&D organization, driving innovation and enhancing market competitiveness in the field of neurological therapeutics.
[object Object]
Preview
5.0
12-02Newsfilter
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer to Advance CNS Drug Development
  • Leadership Enhancement: Ovid Therapeutics has appointed Dr. Petra Kaufmann as Chief Medical Officer, who will guide clinical, medical, and regulatory strategies to advance the company's clinical pipeline of potential best- and first-in-class therapeutic candidates for neuronal imbalance.
  • Extensive Experience: Dr. Kaufmann brings a wealth of experience in CNS therapeutics from her previous roles at Vigil Neuroscience and Novartis Gene Therapies, where she played a key role in the global approval of Zolgensma®, which is expected to significantly enhance Ovid's R&D capabilities.
  • Patient-Focused Development: Emphasizing a patient-centered approach, Dr. Kaufmann is dedicated to advancing therapies for complex neurological conditions, aligning closely with Ovid's mission and potentially accelerating the progress of its GABA-AT inhibitor, OV329.
  • Strategic Collaboration Outlook: Ovid looks forward to collaborating with Dr. Kaufmann to leverage her regulatory experience and clinical principles to advance its broad portfolio of KCC2 direct activators, thereby enhancing the company's competitiveness in the CNS drug market.
[object Object]
Preview
5.0
12-02NASDAQ.COM
Ovid Therapeutics Appoints Petra Kaufmann as Chief Medical Officer

  • Appointment Announcement: Ovid Therapeutics Inc. has appointed Petra Kaufmann as its new chief medical officer.

  • Professional Background: Kaufmann has significant experience in the biopharmaceutical sector and previously led rare-disease research initiatives at the U.S. National Institutes of Health.

  • Previous Role: Before joining Ovid, she was the Chief Medical Officer at Vigil Neuroscience, which was recently acquired by Sanofi.

  • Expertise Areas: In her previous role, Kaufmann managed various functions including medical, clinical, biomarker, patient advocacy, and regulatory aspects.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ovid Therapeutics Inc (OVID) stock price today?

The current price of OVID is 1.62 USD — it has increased 2.53 % in the last trading day.

arrow icon

What is Ovid Therapeutics Inc (OVID)'s business?

Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).

arrow icon

What is the price predicton of OVID Stock?

Wall Street analysts forecast OVID stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OVID is 4.58 USD with a low forecast of 1.50 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ovid Therapeutics Inc (OVID)'s revenue for the last quarter?

Ovid Therapeutics Inc revenue for the last quarter amounts to 132.00K USD, decreased -23.70 % YoY.

arrow icon

What is Ovid Therapeutics Inc (OVID)'s earnings per share (EPS) for the last quarter?

Ovid Therapeutics Inc. EPS for the last quarter amounts to -0.17 USD, decreased -15.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ovid Therapeutics Inc (OVID)'s fundamentals?

The market is revising Downward the revenue expectations for Ovid Therapeutics Inc. (OVID) for FY2025, with the revenue forecasts being adjusted by -2.12% over the past three months. During the same period, the stock price has changed by 31.71%.
arrow icon

How many employees does Ovid Therapeutics Inc (OVID). have?

Ovid Therapeutics Inc (OVID) has 23 emplpoyees as of December 05 2025.

arrow icon

What is Ovid Therapeutics Inc (OVID) market cap?

Today OVID has the market capitalization of 115.36M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free